Sacral neuromodulation with the InterStim™ system for faecal incontinence: results from a prospective French multicentre observational study

Aim The aim of this work was to evaluate the effectiveness, patient satisfaction and quality of life (QoL) and the safety of sacral neuromodulation (SNM) with the InterStimTM system for the treatment of faecal incontinence (FI) and establish whether results published predominantly by expert sites ar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Colorectal disease 2021-06, Vol.23 (6), p.1463-1473
Hauptverfasser: Meurette, Guillaume, Siproudhis, Laurent, Leroi, Anne‐Marie, Damon, Henri, Urs Josef Keller, David, Faucheron, Jean‐Luc, Lehur, Paul A., Orsoni, Pierre Charles, Bridoux, Valerie, Zerbib, Philippe, Dubois, Anne, Rohr, Serge, Barussaud, Marie‐line, Mathonnet, Muriel, Loriau, Jérôme, Etienney, Isabelle, Gravie, Jean Francois, Portier, Guillaume, Escartin, Michel
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aim The aim of this work was to evaluate the effectiveness, patient satisfaction and quality of life (QoL) and the safety of sacral neuromodulation (SNM) with the InterStimTM system for the treatment of faecal incontinence (FI) and establish whether results published predominantly by expert sites are generalisable. Method This is a prospective, multicentre, observational study that invited all French sites treating FI with the InterStim™ system to enrol subjects indicated for an SNM therapy evaluation. Data were collected at three follow‐up visits within 1 and 15 months. Therapeutic effectiveness was evaluated by the reduction in leakages per week and improvements over time in the ability to defer defaecation and QoL (as measured with the Faecal Incontinence Quality of Life score). Safety was assessed through reported adverse events. Results A total of 221 subjects with a mean age of 62.1 years were tested (184 women) and 178 received a permanent implant. For all implanted subjects with diary data at baseline and follow‐up, a reduction in leakage of more than 50% was observed in 80%, 76% and 83% at 1–3, 4–8 and 9–15 months, respectively. The mean number of leakage episodes and urgency improved significantly compared with the baseline (p 
ISSN:1462-8910
1463-1318
DOI:10.1111/codi.15507